Our Team

Mr Hurst is a highly experienced clinical research professional having spent the past five years with a US-based NASDAQ listed company in the clinical development phase of a pharmaceutical grade cannabidiol therapy for a rare disease with orphan designation. Prior to that he spent seventeen years with one of Australia’s foundation early phase clinical trial facilities bringing clinical development services to the global biotechnology and pharmaceutical industries. In the earlier part of his career he spent twenty years in multiple roles in medical research and academic clinical research management at The University of Queensland School of Medicine.

As one of the foundation members of Q-Pharm Pty Ltd in 2002, he was responsible for the establishment of all of the business systems and services for the company, and this included business development and client acquisition & servicing. In his 15 years with the company he was involved with, or personally responsible for, the acquisition of 400 early phase clinical studies from 100 customers resulting in revenue approaching $100 million. As CEO, Mr Hurst oversaw a staff of 50 full time appointments and a pool of casual staff that numbered 100. The company established two new clinical research facilities for the conduct of phase 1 trials.